MiR-223 promotes the doxorubicin resistance of colorectal cancer cells via regulating epithelial-mesenchymal transition by targeting FBXW7.

@article{Ding2018MiR223PT,
  title={MiR-223 promotes the doxorubicin resistance of colorectal cancer cells via regulating epithelial-mesenchymal transition by targeting FBXW7.},
  author={Jieqiong Ding and Zhiwei Zhao and Jia Song and Binghua Luo and Lingping Huang},
  journal={Acta biochimica et biophysica Sinica},
  year={2018},
  volume={50 6},
  pages={
          597-604
        }
}
Although doxorubicin has become a key drug in cancer treatment, the resistance of colorectal carcinoma to doxorubicin is a major problem in clinical practice. F-box and WD repeat domain-containing 7 (FBXW7) plays important roles in human cancers and is one of the major causes of drug resistance. The miR-223/FBXW7 pathway has been reported to be a crucial clue to the mechanism of chemoresistance in many human cancers, such as gastric cancer, breast cancer, and non-small cell lung cancer. However… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 27 REFERENCES

Cancer statistics in China, 2015.

  • CA: a cancer journal for clinicians
  • 2016

The emerging role of miRNAs in combined cancer therapy.

  • Expert opinion on biological therapy
  • 2015
VIEW 1 EXCERPT